Selected Publications:
Dalal Rahul S, Vajravelu Ravy K, Lewis James D, Lichtenstein Gary R: Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals Inflammatory Bowel Diseases : 2019.
Vajravelu Ravy K, Scott Frank I, Mamtani Ronac, Li Hongzhe, Moore Jason H, Lewis James D: Medication class enrichment analysis: a novel algorithm to analyze multiple pharmacologic exposures simultaneously using electronic health record data. Journal of the American Medical Informatics Association : JAMIA 25 (7): 780-789,2018.
Vajravelu Ravy K, Mamtani Ronac, Scott Frank I, Waxman Adam, Lewis James D: Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. Gastroenterology : 2018.
Papamichael Konstantinos, Vajravelu Ravy K, Vaughn Byron P, Osterman Mark T, Cheifetz Adam S: Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. Journal of Crohn's & colitis 12 (7): 804-810,2018.
Osterman Chelsea K, Alanzi Jaber, Lewis James D, Kaufman Elizabeth L, Narayan Vivek, Boursi Ben, Vajravelu Ravy K, Scott Frank I, Malkowicz S Bruce, Mamtani Ronac: Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. Clinical genitourinary cancer 16 (3): 235-239,2018.
Newberry Carolyn, Vajravelu Ravy K, Pickett-Blakely Octavia, Falk Gary, Yang Yu Xiao, Lynch Kristle L: Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category. Digestive diseases and sciences 63 (5): 1243-1249,2018.
Papamichael Konstantinos, Vajravelu Ravy K, Osterman Mark T, Cheifetz Adam S: Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences 63 (3): 761-767,2018.
Vajravelu Ravy K, Osterman Mark T, Aberra Faten N, Roy Jason A, Lichtenstein Gary R, Mamtani Ronac, Goldberg David S, Lewis James D, Scott Frank I: Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflammatory bowel diseases 24 (1): 217-226,2017.
Papamichael Konstantinos, Chachu Karen A, Vajravelu Ravy K, Vaughn Byron P, Ni Josephine, Osterman Mark T, Cheifetz Adam S: Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 15 (10): 1580-1588.e3,2017.
Scott Frank I, Vajravelu Ravy K, Bewtra Meenakshi, Mamtani Ronac, Lee Dale, Goldberg David S, Lewis James D: The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 13 (2): 302-309.e11,2015.
View all publications